Sun Pharmaceutical Industries Limited has announced a postal ballot/e-voting process to seek shareholder approval for three important resolutions, as communicated to the stock exchanges on 17 March 2026. The pharmaceutical major is conducting this exercise under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Resolutions for Shareholder Approval

The company has proposed three resolutions for shareholder consideration through the postal ballot process:

Cost Auditor Remuneration Details

The first resolution seeks ratification of the remuneration payable to M/s. Narasimha Murthy & Co., Cost Accountants (Firm Registration No. 000042), who have been appointed as Cost Auditors for the financial year 2025-26. The proposed remuneration stands at ₹31,26,000 per annum plus reimbursement of out-of-pocket expenses and applicable taxes. This ratification is required under Section 148(3) of the Companies Act, 2013, read with Companies (Audit and Auditors) Rules, 2014.

Memorandum of Association Amendment for Renewable Energy

The second resolution proposes to amend the company's Memorandum of Association by inserting a new Clause (1B) under Clause III (A) – Main Objects. This amendment will enable the company to undertake power generation activities through various renewable energy sources including hydro, solar, nuclear, and other non-conventional energy sources. The proposed change aligns with the company's sustainability goals and Environmental, Social, and Governance (ESG) principles, allowing it to establish captive power plants and potentially sell surplus power to the grid.

Independent Director Re-appointment

The third resolution concerns the re-appointment of Dr. Pawan Goenka (DIN: 00254502) as an Independent Director for a second term of five years, commencing from 21 May 2026 to 20 May 2031. Dr. Goenka, who currently serves as the Lead Independent Director, will continue to hold office even after attaining the age of 75 years during the proposed term. His extensive experience includes leadership roles at Mahindra & Mahindra Limited and current position as Chairperson of IN-SPACE. Dr. Goenka was honored with the Padma Shri in 2025 for his contributions to the space sector and automotive industry.

E-voting Timeline and Process

The company has established a comprehensive timeline for the postal ballot process:

The company has engaged Central Depository Services (India) Limited (CDSL) as the e-voting service provider. KJB & Co. LLP, Practising Company Secretaries, have been appointed as scrutinizers for the voting process, with Mr. Chintan Goswami as the primary scrutinizer and Mr. Alpesh Panchal as the alternate.

Shareholder Participation Guidelines

Shareholders whose names appear on the Register of Members/List of Beneficial Owners as of the cut-off date of 13 March 2026 will be entitled to participate in the voting process. The voting rights will be proportionate to their shareholding in the paid-up equity share capital of the company. The notice has been sent electronically to shareholders with registered email addresses, and physical copies are not being distributed in accordance with regulatory guidelines.

Sun Pharmaceutical Industries Limited has announced the launch of a comprehensive Shareholder Satisfaction Survey aimed at gathering valuable feedback on the services provided by its Registrar and Transfer Agent (RTA). The initiative reflects the company's commitment to maintaining strong relationships with shareholders and continuously improving service delivery.

Survey Details and Timeline

The survey will focus on services rendered by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's RTA. The feedback collection process has been structured with specific parameters to ensure meaningful and relevant responses.

Participation Criteria and Objectives

Participation in the survey is limited to shareholders who have actively availed RTA services during the specified nine-month period from April 1, 2025, to December 31, 2025. This targeted approach ensures that feedback comes from shareholders with direct experience of the services being evaluated.

The company has emphasized that the survey's primary objective is to obtain constructive and experience-based feedback. This approach will enable the company to:

• Improve efficiency in RTA service delivery
• Enhance service quality across all touchpoints
• Increase responsiveness to shareholder needs
• Strengthen overall shareholder services and engagement

Implementation and Communication

Sun Pharmaceutical Industries Limited will send specific communications via email to eligible shareholders, ensuring direct outreach to those who can provide relevant feedback. The company has encouraged all eligible shareholders to actively participate in the survey, highlighting the vital role their feedback will play in service enhancement.

The survey represents part of the company's periodic review process, demonstrating its commitment to continuous improvement in shareholder services. The feedback collected will be used to evaluate current service standards and identify areas for enhancement in the RTA's service delivery model.